|
1）Wagner HN, Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science. 1983; 221: 1264-6
|
|
|
|
2）Hall H, Wedel I, Halldin C, et al. Comparison of the in vitro receptor binding properties of N-[3H]methylspiperone and [3H]raclopride to rat and human brain membranes. J Neurochem. 1990; 55: 2048-57
|
|
|
|
|
3）Laruell M, Wallace E, Seibyl JP, et al. Graphical, kinetic and equilibrium analyses of in [I-123] β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab. 1994; 14: 982-94
|
|
|
|
|
|
4）Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27: 1533-9
|
|
|
|
|
|
5）Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple time uptake data. Generalisations. J Cereb Blood Flow Metab. 1985; 5: 584-90
|
|
|
|
|
|
6）Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990; 10: 740-7
|
|
|
|
|
|
7）Logan J, Fowler JS, Volkow ND, et al. Distri-bution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab. 1996; 16: 834-40
|
|
|
|
|
|
8）Morrish PK, Sawle GV, Brooks DJ. An [F-18]dopa PET and clinical study of the rapid progression in Parkinsons disease. Brain. 1996; 119: 585-91
|
|
|
|
|
|
9）Walker Z, Cummings JL. [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane single-photon emission computed tomography brain imaging in the diagnosis of dementia with Lewy bodies. Alzheimers Dement. 2012; 8: 74-83
|
|
|
|
|
|
10）Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007; 78: 1176-81
|
|
|
|
|
|
11）McKeith I, OBrien J, Walker Z, et al; DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multi-centre study. Lancet Neurol. 2007; 6: 305-13
|
|
|
|
|
|
12）Snow BJ, Tooyama I, McGeer EG, et al. Human positron tomographic [F-18]fluorodopa studies correlate with dopamine cell counts and levels. Ann Neurol. 1993; 34: 324-30
|
|
|
|
|
|
13）Brooks DJ. Imaging end points for monitoring neuroprotection in Parkinsons disease. Ann Neurol. 2003; 53 Suppl 3: S110-9
|
|
|
|
|
|
14）Merek K, Seibyl JP, Zoghbi SS, et al. [I-123] beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinsons dis-ease. Neurology. 1996; 46: 231-7
|
|
|
|
|
|
15）Merek K, Innis R, van Dyck C, et al. [I-123]beta-CIT SPECT imaging assessment of the rate of Parkinsons disease progression. Neurology. 2001; 57: 2089-94
|
|
|
|
|
|
16）Lee CS, Samji A, Sossi V, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinsons disease. Ann Neurol. 2000; 47: 493-503
|
|
|
|
|
|
17）Kung MP, Stevenson DA, PlossiK, et al. [Tc-99m]TRODAT-1: a novel technetium-99m com-plex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24: 372-80
|
|
|
|
|
|
18）Amsterdam JD, Newberg AB, Soeller I, et al. Greater striatal dopamine transporter density may be associated with major depressive episode. J Affect Disord. 2012; 141: 425-31
|
|
|
|
|
|
19）Booij J, de Jong J, de Bruin K, et al. Quan-tification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007; 48: 359-66
|
|
|
|
|
|
20）Varrone A, Tóth M, Steiger C, et al. Kinetic analysis and quantification of the dopamine transporter in the nonhuman primate brain with 11C-PE2I and 18F-FE-PE2I. J Nucl Med. 2011; 52: 132-9
|
|
|
|
|
|
21）Ziebell M, Andersen BB, Thomsen G, et al. Predictive value of dopamine transporter SPECT imaging with [123I]PE2I in patients with subtle parkinsonian symptoms. Eur J Nucl Med Mol Imaging. 2012; 39: 242-50
|
|
|
|
|
|
22）Ziebell M, Holm-Hansen S, Thomsen G, et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J Nucl Med. 2010; 51: 1885-91
|
|
|
|
|
|
23）Catafau AM, Perez V, Penengo MM, et al. SPECT of serotonin transporters using 123I-ADAM: optimal imaging time after bolus injection and long-term test-retest in healthy volunteers. J Nucl Med. 2005; 46: 1301-9
|
|
|
|
|
|
24）Newberg AB, Amsterdam JD, Wintering N, et al. Low brain serotonin transporter binding in major depressive disorder. Psychiatry Res. 2012; 202: 161-7
|
|
|
|
|
|
25）Boileau I, Rusjan P, Houle S, et al. Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: is VMAT2 a stable dopamine neuron bio-marker? J Neurosci. 2008; 28: 9850-6
|
|
|
|
|
|
26）Frey KA, Koeppe RA, Kilbourn MR, et al. Pre-synaptic monoaminergic vesicles in Parkinsons disease and normal aging. Ann Neurol. 1996; 40: 873-84
|
|
|
|
|
|
27）Tong J, Boileau I, Furukawa Y, et al. Distribution of vesicular monoamine transporter 2 protein in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab. 2011; 31: 2065-75
|
|
|
|
|
|
28）Okamura N, Villemagne VL, Drago J, et al. In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with (18)F-AV-133. J Nucl Med. 2010; 51: 223-8
|
|
|
|
|
|
29）Villemagne VL, Okamura N, Pejoska S, et al. In vivo assessment of vesicular monoamine trans-porter type 2 in dementia with lewy bodies and Alzheimer disease. Arch Neurol. 2011; 68: 905-12
|
|
|
|
|
|
30）Momose T, Teramoto A, Nishikawa J, et al. [Clinical application of 11C-NMSP to the patients with pitutitary adenoma other than prolacti-noma]. Kaku Igaku. 1993; 30: 627-35
|
|
|
|
|
31）Mawlawi O, Martinez D, Slifstein M, et al. Imaging human mesolimbic dopamine trans-mission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab. 2001; 21: 1034-57
|
|
|
|
|
|
32）Voon V, Hassan K, Zurowski M, et al. Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology. 2006; 67: 1254-7
|
|
|
|
|
|
33）Voon V, Hassan K, Zurowski M, et al. Prospective prevalence of pathologic gambling and medi-cation association in Parkinson disease. Neurology. 2006; 66: 1750-2
|
|
|
|
|
|
34）Kumakura Y, Danielsen EH, Gjedde A, et al. Elevated [(18)F]FDOPA utilization in the peri-aqueductal gray and medial nucleus accumbens of patients with early Parkinsons disease. Neuro-image. 2010; 49: 2933-9
|
|
|
|
|
|
35）Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkin-sonian patients with pathological gambling: a [11C] raclopride PET study. Brain. 2009; 132(Pt 5): 1376-85
|
|
|
|
|
|
36）Joutsa J, Johansson J, Niemelä S, et al. Meso-limbic dopamine release is linked to symptom severity in pathological gambling. Neuroimage. 2012; 60: 1992-9
|
|
|
|
|
|
37）Paterson LM, Tyacke RJ, Nutt DJ, et al. Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab. 2010; 30: 1682-706
|
|
|
|
|
|
38）Colasanti A, Searle GE, Long CJ, et al. Endo-genous opioid release in the human brain reward system induced by acute amphetamine administ-ration. Biol Psychiatry. 2012; 72: 371-7
|
|
|
|
|